ArticleCureus2024
Efficacy and Safety in the Implantation of Totally Implantable Venous Access Devices by Anesthesiologists: Perspectives From a Retrospective Oncology Cohort.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTotally implantable venous access devices (TIVADs) are widely used in oncology patients to facilitate central venous access. Although they offer benefits, TIVADs can be associated with complications. MATERIALS AND
methodsThis retrospective cohort study included all oncology patients 18 years or older who underwent TIVAD implantation between September 2015 and October 2019. Data were obtained from clinical records at the National Cancer Institute.
resultsA total of 556 TIVAD implantations were performed in cancer patients throughout the study period. The success rate for the first attempts was 91% (506/556). Infectious complications were documented in six patients (1.1%), while non-infectious complications manifested in less than 1% of cases, with hematoma at the insertion site being the most common. Additionally, catheter thrombosis was identified in three asymptomatic patients (0.5%).
conclusionThe implantation of TIVADs by anesthesiologists in cancer patients at the National Cancer Institute was predominantly successful and safe, exhibiting a low complication rate. The findings reinforce the efficacy and safety of the employed technique, exceeding the outcomes reported in existing medical literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.